Promoters of Curis Lifesciences have confirmed that no new encumbrances were created on shares held by the promoter group or Persons Acting in Concert during the financial year ended March 31, 2026. The disclosure, dated April 3, 2026, was submitted to the National Stock Exchange of India Limited and the company's Audit Committee. This declaration ensures transparency regarding the pledging or hypothecation of promoter shares, a key metric for investor risk assessment.

The compliance was filed under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The regulation mandates annual disclosures by promoters regarding any encumbrance on shares held directly or indirectly. The confirmations were provided by Jaimik Mansukhlal Patel, Dharmesh Dasharathbhai Patel, Piyush Gordhanbhai Antala, and Siddhant Jayantibhai Pawasia.

Promoter Disclosures

The following table summarizes the disclosures made by the promoters:

Each promoter explicitly stated that no encumbrance was made other than those already disclosed to the exchanges. The letters addressed to the Manager of the National Stock Exchange and the Chairman of the Audit Committee of Curis Lifesciences Limited were signed and submitted for record purposes.

Curis Lifesciences reported an 11.4% increase in net profit to ₹691.63 lakh for the year ended March 31, 2026, compared to ₹620.64 lakh in the previous year. Revenue from operations rose 20.6% to ₹6062.88 lakh from ₹5025.86 lakh in FY25. The Board of Directors approved the audited standalone financial results for the half year and year ended March 31, 2026, at a meeting held on May 30, 2026.

The company’s total income for FY26 stood at ₹6091.04 lakh, up from ₹5027.08 lakh in the previous year. Total expenses increased to ₹5133.41 lakh from ₹4129.52 lakh. Profit before tax for the year was ₹956.16 lakh, compared to ₹898.80 lakh in the prior year. For the half year ended March 31, 2026, net profit was ₹270.55 lakh on revenue of ₹3271.99 lakh.

Financial Performance

The earnings per share (EPS) for the year ended March 31, 2026, was ₹10.26, compared to ₹10.87 in the previous year. The company stated that EPS calculations were adjusted for a bonus issue of shares in the ratio of 10:1 during FY 2024-25 and a fresh issue of shares following its Initial Public Offering (IPO). The IPO, comprising 21,50,000 equity shares, was listed on the SME Emerge Platform of NSE Limited on November 14, 2025.

Strategic Developments

During the half year ended March 31, 2026, the company agreed to make a strategic investment in Uninova Lifesciences Private Limited by acquiring 51% of the share capital. Curis Lifesciences has already provided ₹20.655 lakh to promoters for this acquisition. Uninova Lifesciences Private Limited will become a subsidiary upon formalization of the share agreement.

Financial Position

The company’s total assets as of March 31, 2026, stood at ₹8152.07 lakh, up from ₹4259.52 lakh in the previous year. Shareholders' funds increased to ₹4735.77 lakh, driven by a rise in share capital to ₹808.44 lakh and reserves and surplus to ₹3927.33 lakh. Cash and cash equivalents improved significantly to ₹316.51 lakh from ₹30.36 lakh.